Please login or register to print this page.

ARTICLE CONTRIBUTORS

European Society of Cardiology

Clinical Articles, News & Views

Urgent call for cardiovascular R&D revival to halt growing CVD epidemic

A resurgence in cardiovascular R&D is urgently needed to curb a new epidemic of cardiovascular diseases, according to results1 published recently in the European Heart Journal.

The report outlines the views of the Cardiovascular Round Table (CRT), an independent forum established by the European Society of Cardiology (ESC) and comprised of cardiologists and representatives of the pharmaceutical and medical device industries.

The CRT paper outlines how, compared with other medical areas, CVD related R&D is in steep decline. The authors state: “This is mostly due to the impact of complex regulation which drives up development costs and delays time-to-market for new cardiovascular drugs.”

They add: “The recent closure of mainstream R&D facilities in Europe is clear evidence of an investment crisis that has to be addressed and a regulatory environment that must be simplified without compromising patients’ safety which is our utmost duty.”

Research and development has moved to other geographic regions and medical areas that are likely to yield better returns, they observe, and there is a risk that cardiologists will not have access to the optimum treatment techniques at a time when a new CVD epidemic is gaining ground in Europe.

The authors recommend that a forum be established to discuss how to rejuvenate cardiovascular R&D in Europe. It should consist of EU representatives, national healthcare authorities and finance ministries, academia, medical societies and representatives of the pharmaceutical and medical device industries.

Their agenda should include:

  • Reviewing the issues driving R&D investment to other geographical and medical areas
  • Simplifying the clinical trials environment
  • Targeting EU funding through tax incentives and sponsored development programmes
  • Reviewing patent duration in the context of development timescales and investment
  • Encouraging cross-border and cross-discipline collaboration and networking.

Lead author Professor Michel Komajda (Pitié Salpetriere Hospital, Paris) said: “Research and development in pharmacology for the management of cardiovascular diseases has been extremely powerful and efficient in Europe so far. The 30 day mortality after myocardial infarction has been more than halved in 20 years thanks to the new anti-thrombotic agents. The European economy has also benefited from the creation of high and middle profile jobs.”

“As a professional society, the ESC believes it is our task to highlight how declining cardiovascular innovation threatens the availability of new treatments in Europe, a situation which leaves European citizens short of needed innovations and risks damaging the economy. We set up the CRT to increase awareness of these issues and kick start solutions,” Professor Komajda added.

He concludes: “A new epidemic of cardiovascular diseases is taking hold in Europe. Urgent steps are needed to halt this epidemic by removing the barriers to cardiovascular R&D in Europe.”

References

1. Komajda M, Coats A, Cowie MR, et al. Championing cardiovascular health innovation in Europe. Eur Heart J 2013. http://dx.doi.org/10.1093/eurheartj/eht211

Published on: July 30, 2013

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.